Lymphotoxin alpha

Last updated • 6 min readFrom Wikipedia, The Free Encyclopedia
LTA
Protein LTA PDB 1tnr.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases LTA , LT, TNFB, TNFSF1, Lymphotoxin alpha, TNLG1E
External IDs OMIM: 153440; MGI: 104797; HomoloGene: 497; GeneCards: LTA; OMA:LTA - orthologs
Orthologs
SpeciesHumanMouse
Entrez

4049

16992

Ensembl

ENSMUSG00000024402

UniProt

P01374

P09225

RefSeq (mRNA)

NM_000595
NM_001159740

NM_010735

RefSeq (protein)

NP_000586
NP_001153212

NP_034865

Location (UCSC) Chr 6: 31.57 – 31.57 Mb Chr 17: 35.42 – 35.42 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Lymphotoxin-alpha (LT-α) formerly known as tumor necrosis factor-beta (TNF-β) [5] [6] is a protein that in humans is encoded by the LTA gene. [7] [8] Belonging to the hematopoietic cell line, LT-α exhibits anti-proliferative activity and causes the cellular destruction of tumor cell lines. [7] As a cytotoxic protein, LT-α performs a variety of important roles in immune regulation depending on the form that it is secreted as. Unlike other members of the TNF superfamily, LT-α is only found as a soluble homotrimer, when found at the cell surface it is found only as a heterotrimer with LTβ. [6]

Contents

LT-α has a significant impact on the maintenance of the immune system including the development of secondary lymphoid organs. [9] [10] Absence of LT-α leads to the disruption of gastrointestinal development, prevents Peyer's patch development, and results in a disorganized spleen. [11]

As a signaling molecule, LT-α is involved in the regulation of cell survival, proliferation, differentiation, and apoptosis. [12] LT-α plays an important role in innate immune regulation and its presence has been shown to prevent tumor growth and destroy cancerous cell lines. [13] In contrast, unregulated expression of LT-α can result in a constantly active signaling pathway, thus leading to uncontrolled cellular growth and creation of tumors. [12] Hence depending on the context, LT-α may function to prevent growth of cancer cells or facilitate the development of tumors. Furthermore, LT-α effects depend on the type of organ it acts upon, type of cancer cells, cellular environment, gender, and time of effect during an immune response. [14] [13]

Gene

The human gene encoding for LT-α was cloned in 1985. [7] [15] The gene of LT-α is located on chromosome 6 and is in close proximity of the gene encoding major histocompatibility complex. [16]

Structure

LT-α is translated as a 25 kDa glycosylated polypeptide with 171 amino acid residues. [8] Furthermore, human LT-α is 72% identical to mouse LT-α at the protein's primary sequence. [17]

LTα expression is highly inducible and when secreted, forms a soluble homotrimeric molecule. LT-α can also form heterotrimers with lymphotoxin-beta, which anchors lymphotoxin-alpha to the cell surface. The interaction between LT-α and LT-β results in the formation of a membrane bound complex (LT-α1-β2). [10]

Function

Lymphotoxin alpha, a member of the tumor necrosis factor superfamily, is a cytokine produced by lymphocytes. LT-α1-β2 can interact with receptors such as LT-β receptors. [12] Absence of LT-β on cell surfaces will diminish the ability of LT-α to form LT-α1-β2, thus decreasing its effective ability as a cytokine. [9] [10] LT-α mediates a large variety of inflammatory, immunostimulatory, and antiviral responses. LT-α is also involved in the formation of secondary lymphoid organs during development and plays a role in apoptosis. [18]

In LT-α knockout mice, Peyer's patches and lymph nodes will fail to develop, thus illustrating the cytokine's essential role in immunological development. [19]

As a cytotoxic protein, LT-α causes the destruction of cancerous cell lines, activates signaling pathways, and effectively kills transformed tumor cells. [9] [12] However, mice with overexpression of LT-α or LT-β showed increased tumor growth and metastasis in several models of cancer. In other studies, mice with gene knockout of LT-α showed enhanced tumor growth, implicating possible protective role of LT-α in cancer. However, these studies utilized mice with complete LT-α deficiency that did not allow to distinguish effects of soluble versus membrane-associated LT. [20]

LT-α mediated signaling pathway

As a member of the TNF family, LT-α binds to various receptors and activates the NF-κB pathway, thus promoting immune regulation through the innate immune response. [12] In order for activation to occur, LT-α must form a complex with LT-β to form the LT-α1-β2 complex. Formation of LT-α1-β2 complex enables binding to LT-β receptors and subsequent activation of signaling pathways. [21] Activation of signaling pathways such as NF-κB ultimately leads to various cellular fates, including cell proliferation and cell death. After LT-β receptor activation, IKK-α, β, and γ are produced, which increases degradation of I-κB, an inhibitor of NF-kB, and produce NF-kB1 (p50) and ReIA (p60). [21] The production of NF-kB1 and ReIA increases rates of gene transcription of cytokines and inflammatory-inducing molecules. [21] [22]

Anti-carcinogenic properties

Activation of LT-β receptors is capable of inducing cell death of cancerous cells and suppressing tumor growth. [23] [24] The process of cell death is mediated by the presence of IFN-γ and can involve apoptotic or necrotic pathways. [23] It is seen that LT-β receptors facilitate the upregulation of adhesion molecules and recruit lymphocytes to tumor cells to combat tumor growth. [7] [12] In other words, LT-α interactions with LT-β receptors can increase anti-tumor effects through direct destruction of tumor cells.

Pro-carcinogenic properties

However, recent studies have shown the contribution of LT-α mediated signaling to the development of cancer. [9] [12] [13] [14] As mentioned previously, LT-α signaling can promote inflammatory responses, but prolonged inflammation can cause serious cellular damage and increase the risk of certain diseases including cancer. [13] Thus, mutations in regulatory factors in LT-α signaling pathways can promote cell signaling disruptions and encourage the creation of cancerous cell lines. One of these mutations includes constant binding of LT-α1-β2 complex to LT-β receptors, which results in the constant activation of the NF-κB alternative pathway. [12] [13] Presence of a constitutively active NF-κB pathway manifests in multiple myeloma and other cancer-related diseases. [12] Removal of LT-β receptors has shown to inhibit tumor growth and decrease angiogenesis. [13] Thus, lymphotoxin and its downstream signaling via the NF-κB pathway illustrate the cytokine's influence on tumor development and metastasis.

A fully humanized anti-LT-α antibody (Pateclizumab or MLTA3698A) has been shown to react with both LT-α and LT-β. [9] Clinical trials involving this antibody have yet to be employed, but the creation of this antibody offers alternative inhibitory methods for the NF-κB pathway.

Effects on gastrointestinal system

During embryonic development, LT-α signaling plays an active part in the formation of the gastrointestinal immune system. [11] In particular, LT-α mediated signaling is responsible for the development of intestinal lymphoid structures such as Peyer’s patches. [25] [26] This intestinal lymphoid follicle plays an important role in the immune system of the digestive tract.

Peyer’s patches are highly specialized lymphoid nodules located in the intestine. They are surrounded by follicle-associated epithelium and are able to interact with other immune cells through the transcytosis of foreign antigens. [27] In addition to this function, Peyer’s patches facilitate the production Ig-A producing immunocytes, thus increasing the efficacy of the adaptive immune system. [28]

The development of Peyer’s patches requires the binding and activation of LT-β receptor with LT-α1-β2 complex. Experiments involving transgenic mice have shown that the absence of LT-α resulted in the lack of Peyer’s patches and other lymph nodes. [11] The lack of Peyer’s patches and other lymph nodes have also been shown to reduce levels of Ig-A. [11] Being the most produced immunoglobulin, Ig-A protects against mucosal pathogens by regulating bacterial growth and inhibiting antigen adhesion to the intestine under normal conditions. [29] Reduced levels of Ig-A greatly diminishes gut immune regulation and deregulate protection against microbes, thereby emphasizing the importance of LT-mediated response for the expression of Ig-A.

Nomenclature

Discovered by Granger and his research group in 1968, LT-alpha was known as lymphotoxin. [30] As years progressed, its name was changed to tumor necrosis factor-beta (TNF-β). [31] Later discovery of LT-β and LT-α1-β2 complex prompted the disposal of TNF-β and the subdivision of LT into two classes: LT-α and LT-β. [32] [33]

Interactions

Lymphotoxin alpha has been shown to interact with LTB. [34] [35] [36]

See also

Related Research Articles

<span class="mw-page-title-main">Cytokine</span> Broad and loose category of small proteins important in cell signaling

Cytokines are a broad and loose category of small proteins important in cell signaling. Due to their size, cytokines cannot cross the lipid bilayer of cells to enter the cytoplasm and therefore typically exert their functions by interacting with specific cytokine receptors on the target cell surface. Cytokines have been shown to be involved in autocrine, paracrine and endocrine signaling as immunomodulating agents.

<span class="mw-page-title-main">Tumor necrosis factor</span> Protein

Tumor necrosis factor ('TNF), also known as cachexin or cachectin, is a cytokine and a member of the TNF superfamily, which comprises various transmembrane proteins with a homologous TNF domain. Initially referred to as TNFα, this cytokine was the first to be identified as an adipokine, secreted by adipose tissue. TNF signaling occurs through two receptors: TNFR1 and TNFR2. TNFR1 is widely expressed across most cell types and is typically associated with pro-inflammatory and apoptotic signaling. In contrast, TNFR2 is mainly found on endothelial, epithelial, and immune cells, where it mediates anti-inflammatory responses and promotes cell proliferation.

<span class="mw-page-title-main">Interleukin 12</span> Interleukin

Interleukin 12 (IL-12) is an interleukin that is naturally produced by dendritic cells, macrophages, neutrophils, helper T cells and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. IL-12 belongs to the family of interleukin-12. IL-12 family is unique in comprising the only heterodimeric cytokines, which includes IL-12, IL-23, IL-27 and IL-35. Despite sharing many structural features and molecular partners, they mediate surprisingly diverse functional effects.

<span class="mw-page-title-main">Transforming growth factor beta</span> Cytokine

Transforming growth factor beta (TGF-β) is a multifunctional cytokine belonging to the transforming growth factor superfamily that includes three different mammalian isoforms and many other signaling proteins. TGFB proteins are produced by all white blood cell lineages.

<span class="mw-page-title-main">TNF receptor superfamily</span> Protein superfamily of cytokine receptors

The tumor necrosis factor receptor superfamily (TNFRSF) is a protein superfamily of cytokine receptors characterized by the ability to bind tumor necrosis factors (TNFs) via an extracellular cysteine-rich domain. With the exception of nerve growth factor (NGF), all TNFs are homologous to the archetypal TNF-alpha. In their active form, the majority of TNF receptors form trimeric complexes in the plasma membrane. Accordingly, most TNF receptors contain transmembrane domains (TMDs), although some can be cleaved into soluble forms, and some lack a TMD entirely. In addition, most TNF receptors require specific adaptor protein such as TRADD, TRAF, RIP and FADD for downstream signalling. TNF receptors are primarily involved in apoptosis and inflammation, but they can also take part in other signal transduction pathways, such as proliferation, survival, and differentiation. TNF receptors are expressed in a wide variety of tissues in mammals, especially in leukocytes.

Lymphotoxin is a member of the tumor necrosis factor (TNF) superfamily of cytokines, whose members are responsible for regulating the growth and function of lymphocytes and are expressed by a wide variety of cells in the body.

<span class="mw-page-title-main">CD134</span> Protein-coding gene in humans

Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor, is a member of the TNFR-superfamily of receptors which is not constitutively expressed on resting naïve T cells, unlike CD28. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation. Expression of OX40 is dependent on full activation of the T cell; without CD28, expression of OX40 is delayed and of fourfold lower levels.

<span class="mw-page-title-main">TRAF2</span> Protein-coding gene in humans

TNF receptor-associated factor 2 is a protein that in humans is encoded by the TRAF2 gene.

<span class="mw-page-title-main">Lymphotoxin beta receptor</span>

Lymphotoxin beta receptor (LTBR), also known as tumor necrosis factor receptor superfamily member 3 (TNFRSF3), is a cell surface receptor for lymphotoxin involved in apoptosis and cytokine release. It is a member of the tumor necrosis factor receptor superfamily.

<span class="mw-page-title-main">IKK2</span> Protein-coding gene in the species Homo sapiens

IKK-β also known as inhibitor of nuclear factor kappa-B kinase subunit beta is a protein that in humans is encoded by the IKBKB gene.

<span class="mw-page-title-main">TRAF1</span> Protein-coding gene in the species Homo sapiens

TNF receptor-associated factor 1 is a protein that in humans is encoded by the TRAF1 gene.

<span class="mw-page-title-main">TRAF3</span> Protein-coding gene in the species Homo sapiens

TNF receptor-associated factor (TRAF3) is a protein that in humans is encoded by the TRAF3 gene.

<span class="mw-page-title-main">Lymphotoxin beta</span> Protein-coding gene in the species Homo sapiens

Lymphotoxin-beta (LT-beta) also known as tumor necrosis factor C (TNF-C) is a protein that in humans is encoded by the LTB gene.

<span class="mw-page-title-main">Interferon alpha-1</span> Protein-coding gene in the species Homo sapiens

Interferon alpha-1 is a protein that in humans is encoded by the IFNA1 gene.

<span class="mw-page-title-main">MAP3K14</span> Protein-coding gene in the species Homo sapiens

Mitogen-activated protein kinase kinase kinase 14 (MAP3K14), also known as NF-kappa-B-inducing kinase (NIK), is a MAP kinase kinase kinase enzyme that in humans is encoded by the MAP3K14 gene.

<span class="mw-page-title-main">LIGHT (protein)</span> Secreted protein of the TNF superfamily

LIGHT, also known as tumor necrosis factor superfamily member 14 (TNFSF14), is a secreted protein of the TNF superfamily. It is recognized by herpesvirus entry mediator (HVEM), as well as decoy receptor 3.

<span class="mw-page-title-main">TNFRSF18</span> Protein-coding gene in the species Homo sapiens

Tumor necrosis factor receptor superfamily member 18 (TNFRSF18), also known as glucocorticoid-induced TNFR-related protein (GITR) or CD357. GITR is encoded and tnfrsf18 gene at chromosome 4 in mice. GITR is type I transmembrane protein and is described in 4 different isoforms. GITR human orthologue, also called activation-inducible TNFR family receptor (AITR), is encoded by the TNFRSF18 gene at chromosome 1.

The following outline is provided as an overview of and topical guide to immunology:

Innate lymphoid cells (ILCs) are the most recently discovered family of innate immune cells, derived from common lymphoid progenitors (CLPs). In response to pathogenic tissue damage, ILCs contribute to immunity via the secretion of signalling molecules, and the regulation of both innate and adaptive immune cells. ILCs are primarily tissue resident cells, found in both lymphoid, and non- lymphoid tissues, and rarely in the blood. They are particularly abundant at mucosal surfaces, playing a key role in mucosal immunity and homeostasis. Characteristics allowing their differentiation from other immune cells include the regular lymphoid morphology, absence of rearranged antigen receptors found on T cells and B cells, and phenotypic markers usually present on myeloid or dendritic cells.

Immunology is the study of the immune system during health and disease. Below is a list of immunology-related articles.

References

  1. 1 2 3 ENSG00000223919, ENSG00000173503, ENSG00000226275, ENSG00000230279, ENSG00000238130, ENSG00000226979 GRCh38: Ensembl release 89: ENSG00000231408, ENSG00000223919, ENSG00000173503, ENSG00000226275, ENSG00000230279, ENSG00000238130, ENSG00000226979 – Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000024402 – Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ "Lymphotoxin Alpha - an overview | ScienceDirect Topics".
  6. 1 2 Calmon-Hamaty, Flavia; Combe, Bernard; Hahne, Michael; Morel, Jacques (2011). "Lymphotoxin α revisited: general features and implications in rheumatoid arthritis". Arthritis Research & Therapy. 13 (4): 232. doi: 10.1186/ar3376 . PMC   3239340 . PMID   21861866.
  7. 1 2 3 4 Nedwin GE, Naylor SL, Sakaguchi AY, Smith D, Jarrett-Nedwin J, Pennica D, Goeddel DV, Gray PW (September 1985). "Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization". Nucleic Acids Research. 13 (17): 6361–73. doi:10.1093/nar/13.17.6361. PMC   321958 . PMID   2995927.
  8. 1 2 Aggarwal BB, Eessalu TE, Hass PE (February 1986). "Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon". Nature. 318 (6047): 665–7. doi:10.1038/318665a0. PMID   3001529. S2CID   4341571.
  9. 1 2 3 4 5 Ruddle NH (April 2014). "Lymphotoxin and TNF: how it all began-a tribute to the travelers". Cytokine & Growth Factor Reviews. 25 (2): 83–9. doi:10.1016/j.cytogfr.2014.02.001. PMC   4027955 . PMID   24636534.
  10. 1 2 3 Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper MD, Browning JL, Sedgwick JD, Cyster JG (January 1999). "Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen". The Journal of Experimental Medicine. 189 (2): 403–12. doi:10.1084/jem.189.2.403. PMC   2192983 . PMID   9892622.
  11. 1 2 3 4 Gubernatorova EO, Tumanov AV (November 2016). "Tumor Necrosis Factor and Lymphotoxin in Regulation of Intestinal Inflammation". Biochemistry. Biokhimiia. 81 (11): 1309–1325. doi:10.1134/S0006297916110092. PMID   27914457. S2CID   15764230.
  12. 1 2 3 4 5 6 7 8 9 Bauer J, Namineni S, Reisinger F, Zöller J, Yuan D, Heikenwälder M (2012-01-01). "Lymphotoxin, NF-ĸB, and cancer: the dark side of cytokines". Digestive Diseases. 30 (5): 453–68. doi:10.1159/000341690. PMID   23108301. S2CID   13165828.
  13. 1 2 3 4 5 6 Fernandes MT, Dejardin E, dos Santos NR (April 2016). "Context-dependent roles for lymphotoxin-β receptor signaling in cancer development". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1865 (2): 204–19. doi:10.1016/j.bbcan.2016.02.005. hdl: 10400.1/9527 . PMID   26923876.
  14. 1 2 Wong GH, Kaspar RL, Zweiger G, Carlson C, Fong SE, Ehsani N, Vehar G (January 1996). "Strategies for manipulating apoptosis for cancer therapy with tumor necrosis factor and lymphotoxin". Journal of Cellular Biochemistry. 60 (1): 56–60. doi: 10.1002/(SICI)1097-4644(19960101)60:1<56::AID-JCB9>3.0.CO;2-2 . PMID   8825416. S2CID   42014048.
  15. ↑ Pokholok DK, Maroulakou IG, Kuprash DV, Alimzhanov MB, Kozlov SV, Novobrantseva TI, Turetskaya RL, Green JE, Nedospasov SA (January 1995). "Cloning and expression analysis of the murine lymphotoxin beta gene". Proceedings of the National Academy of Sciences of the United States of America. 92 (3): 674–8. Bibcode:1995PNAS...92..674P. doi: 10.1073/pnas.92.3.674 . PMC   42682 . PMID   7846035.
  16. ↑ Nedospasov SA, Hirt B, Shakhov AN, Dobrynin VN, Kawashima E, Accolla RS, Jongeneel CV (October 1986). "The genes for tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) are tandemly arranged on chromosome 17 of the mouse". Nucleic Acids Research. 14 (19): 7713–25. doi:10.1093/nar/14.19.7713. PMC   311791 . PMID   3490653.
  17. ↑ Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV (1984). "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin". Nature. 312 (5996): 724–9. Bibcode:1984Natur.312..724P. doi:10.1038/312724a0. hdl: 21.11116/0000-0000-D4ED-6 . PMID   6392892. S2CID   4245957.
  18. ↑ "Entrez Gene: LTA lymphotoxin alpha (TNF superfamily, member 1)".
  19. ↑ Akirav E, Liao S, Ruddle N (2008). "2. Lymphoid Tissues and Organs". In Paul W (ed.). Fundamental Immunology (6th ed.). Lippincott Williams & Wilkins. pp. 27–55. ISBN   978-0-7817-6519-0.
  20. ↑ Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA (January 2017). "TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis". Cytokine. 89: 127–135. doi:10.1016/j.cyto.2016.01.021. PMID   26854213.
  21. 1 2 3 Müller JR, Siebenlist U (April 2003). "Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways". The Journal of Biological Chemistry. 278 (14): 12006–12. doi: 10.1074/jbc.M210768200 . PMID   12556537.
  22. ↑ Yilmaz ZB, Weih DS, Sivakumar V, Weih F (January 2003). "RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF". The EMBO Journal. 22 (1): 121–30. doi:10.1093/emboj/cdg004. PMC   140043 . PMID   12505990.
  23. 1 2 Browning JL, Miatkowski K, Sizing I, Griffiths D, Zafari M, Benjamin CD, Meier W, Mackay F (March 1996). "Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines". The Journal of Experimental Medicine. 183 (3): 867–78. doi:10.1084/jem.183.3.867. PMC   2192357 . PMID   8642291.
  24. ↑ Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, et al. (October 2006). "Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy". Cancer Research. 66 (19): 9617–24. doi: 10.1158/0008-5472.CAN-06-0217 . PMID   17018619.
  25. ↑ Fu YX, Chaplin DD (1999). "Development and maturation of secondary lymphoid tissues". Annual Review of Immunology. 17: 399–433. doi:10.1146/annurev.immunol.17.1.399. PMID   10358764.
  26. ↑ Randall TD, Carragher DM, Rangel-Moreno J (2008). "Development of secondary lymphoid organs". Annual Review of Immunology. 26: 627–50. doi:10.1146/annurev.immunol.26.021607.090257. PMC   2590644 . PMID   18370924.
  27. ↑ Cornes JS (June 1965). "Number, size, and distribution of Peyer's patches in the human small intestine: Part I The development of Peyer's patches". Gut. 6 (3): 225–9. doi:10.1136/gut.6.3.225. PMC   1552287 . PMID   18668776.
  28. ↑ Craig SW, Cebra JJ (July 1971). "Peyer's patches: an enriched source of precursors for IgA-producing immunocytes in the rabbit". The Journal of Experimental Medicine. 134 (1): 188–200. doi:10.1084/jem.134.1.188. PMC   2139023 . PMID   4934147.
  29. ↑ Făgărășan S.; Honjo T. (January 2003). "Intestinal IgA synthesis: regulation of front-line body defences". Nature Reviews. Immunology. 3 (1): 63–72. doi:10.1038/nri982. PMID   12511876. S2CID   2586305.
  30. ↑ Williams TW, Granger GA (September 1968). "Lymphocyte in vitro cytotoxicity: lymphotoxins of several mammalian species". Nature. 219 (5158): 1076–7. Bibcode:1968Natur.219.1076W. doi:10.1038/2191076a0. PMID   5673378. S2CID   4171855.
  31. ↑ Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA (September 1985). "Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors". Journal of Immunology. 135 (3): 2069–73. doi: 10.4049/jimmunol.135.3.2069 . PMID   3926894. S2CID   22218299.
  32. ↑ Browning JL, Ngam-ek A, Lawton P, DeMarinis J, Tizard R, Chow EP, Hession C, O'Brine-Greco B, Foley SF, Ware CF (March 1993). "Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface". Cell. 72 (6): 847–56. doi:10.1016/0092-8674(93)90574-a. PMID   7916655. S2CID   28961163.
  33. ↑ Koni PA, Sacca R, Lawton P, Browning JL, Ruddle NH, Flavell RA (April 1997). "Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice". Immunity. 6 (4): 491–500. doi: 10.1016/s1074-7613(00)80292-7 . PMID   9133428.
  34. ↑ Williams-Abbott L, Walter BN, Cheung TC, Goh CR, Porter AG, Ware CF (August 1997). "The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha1beta2 heterotrimeric ligand". The Journal of Biological Chemistry. 272 (31): 19451–6. doi: 10.1074/jbc.272.31.19451 . PMID   9235946.
  35. ↑ Browning JL, Sizing ID, Lawton P, Bourdon PR, Rennert PD, Majeau GR, Ambrose CM, Hession C, Miatkowski K, Griffiths DA, Ngam-ek A, Meier W, Benjamin CD, Hochman PS (October 1997). "Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes". Journal of Immunology. 159 (7): 3288–98. doi: 10.4049/jimmunol.159.7.3288 . PMID   9317127. S2CID   25608697.
  36. ↑ Browning JL, Dougas I, Ngam-ek A, Bourdon PR, Ehrenfels BN, Miatkowski K, Zafari M, Yampaglia AM, Lawton P, Meier W (January 1995). "Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors". Journal of Immunology. 154 (1): 33–46. doi: 10.4049/jimmunol.154.1.33 . PMID   7995952. S2CID   22313274.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.